MALAT1 was identified as one of the most abundant transcripts in CRPC biopsies [378], and high expression of MALAT1 was proposed to stratify patients with advanced PCa who would benefit from Enzalutamide treatment [379]. Here, MALAT1 is linked to posterior cortical atrophy.